A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

This trial is testing CD70-targeted CAR T-cell therapy — a treatment that engineers a patient's own immune cells to hunt down and destroy cancer cells carrying the CD70 protein — for women with advanced or metastatic gynecological cancers (such as ovarian, cervical, or uterine cancer) that no longer respond to standard treatments. **You may be eligible if...** - You are 18 or older - You have an advanced or metastatic gynecological cancer confirmed by biopsy - Your tumor tests positive for the CD70 protein (confirmed by a pathology test showing strong positivity) - Your cancer has stopped responding to or you cannot tolerate standard treatments (surgery, chemotherapy, radiation, targeted therapy) - You have at least one measurable tumor area on imaging - You are in reasonably good health and your major organs are functioning adequately - Your expected survival is more than 12 weeks **You may NOT be eligible if...** - Your tumor does not express the CD70 protein - Your cancer has responded adequately to available standard treatments - You have serious heart, kidney, or liver problems - You have active serious infections - You have significant psychiatric conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.